Dissident AIDS Database
|HIV drugs||Interleukin-2||Side effects||General|
|Interleukin 2 Treatment for HIV Infection.|| ||Blankson J, Siliciano RF.
| ||“The potential benefit gained from an increase in the number of CD4 cells needs to be balanced against the toxic effects of the treatment. In the study by Davey et al, 54% of the patients receiving IL-2 [Interleukin-2] with HAART had serious adverse effects compared with 16% of patients receiving HAART alone. Studies demonstrating a clinical benefit from IL-2 therapy are needed before it is adopted as a complementary option in conjunction with antiretroviral therapy.”|
| ||JAMA. 2000 Jul 12;284(2):236-238.||2000|
|Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy: A Randomized Controlled Trial.|| ||Davey RT Jr et al.
| ||“IL-2 [Interleukin-2] recipients experienced more adverse events than recipients of ART [standard antiretroviral therapy, not including IL-2] alone. The most common toxic effects experienced by IL-2-treated patients were constitutional symptoms of fever, fatigue, and myalgias of varying severity... Despite these measures, serious (at least grade 3) adverse events occurred in 20 (54%) of 37 evaluable IL-2 recipients and 7 (16%) of 43 ART recipients.”|
| ||JAMA. 2000 Jul 12;284(2):183-189.||2000|
|Sarcoidosis in a patient with acquired immunodeficiency syndrome treated with Interleukin-2.|| ||Blanche P et al.
| ||“We report a case of sarcoidosis beginning after 2 months of interleukin-2 (IL-2) therapy in a patient with HIV who had undectable plasmatic viral load under HAART and we discuss possible mechanisms...IL-2 [Interleukin-2] plays a pivotal role in the pathology of sarcoidosis [formation of nodules in the lungs, liver, lymph nodes and salivary glands].”|
| ||Clin Infect Dis. 2000 Dec;31:1493-4||2000|